Natixis Advisors
UTHR icon

Natixis Advisors’s United Therapeutics UTHR Stock Holding History

Natixis Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39M Buy
17,340
+2,091
+14% +$1.18M 0.01% 742
2026
Q1 		$9.04M Buy
15,249
+3,481
+30% +$1.73M 0.01% 686
2025
Q4 		$5.73M Buy
11,768
+53
+0.5% +$24.7K 0.01% 782
2025
Q3 		$4.91M Sell
11,715
-533
-4% -$179K 0.01% 842
2025
Q2 		$3.52M Sell
12,248
-106,334
-90% -$31.8M 0.01% 906
2025
Q1 		$36.6M Buy
118,582
+104,847
+763% +$35.9M 0.07% 285
2024
Q4 		$4.85M Sell
13,735
-3,276
-19% -$1.2M 0.01% 831
2024
Q3 		$6.1M Sell
17,011
-739
-4% -$250K 0.01% 778
2024
Q2 		$5.65M Buy
17,750
+1,169
+7% +$309K 0.01% 757
2024
Q1 		$3.81M Buy
16,581
+531
+3% +$120K 0.01% 867
2023
Q4 		$3.53M Sell
16,050
-5,269
-25% -$1.21M 0.01% 854
2023
Q3 		$4.82M Buy
21,319
+7,702
+57% +$1.77M 0.01% 717
2023
Q2 		$3.01M Buy
13,617
+1,612
+13% +$357K 0.01% 858
2023
Q1 		$2.69M Buy
+12,005
New +$2.96M 0.01% 862
2014
Q2 		– Sell
-6,026
Closed -$567K – 1331
2014
Q1 		$567K Buy
6,026
+62
+1% +$6.34K 0.01% 917
2013
Q4 		$674K Buy
5,964
+126
+2% +$11.4K 0.01% 833
2013
Q3 		$460K Buy
5,838
+643
+12% +$47K 0.01% 862
2013
Q2 		$342K Buy
+5,195
New +$335K 0.01% 899

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Natixis Advisors's UTHR Position: Q2 2026 in Review

Natixis Advisors increased its United Therapeutics (UTHR) stake by 14% in Q2 2026, buying an estimated $1.18M and bringing the position to 17,340 shares worth $9.39M. The position accounts for 0.01% of the portfolio, ranked #742.

Natixis Advisors first reported a position in UTHR in Q2 2013 and has held it in 18 quarters since. The position peaked at $36.6M in Q1 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Natixis Advisors held 17,340 shares of United Therapeutics worth $9.39M as of Q2 2026.
  • Natixis Advisors bought 2,091 United Therapeutics shares in Q2 2026, an estimated $1.18M.
  • United Therapeutics made up 0.01% of Natixis Advisors's portfolio in Q2 2026, its #742 holding.
  • Natixis Advisors first reported a position in United Therapeutics in Q2 2013 and has held it in 18 quarters since.
  • Natixis Advisors's United Therapeutics position peaked at $36.6M in Q1 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.